Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
23andme Holding Co.
Headquarters: Mountain View, CA, United States of America
Website: http://www.23andme.com
Year Founded: 2006
Status: Public
Industry Sector: HealthTechnology
CEO: Joseph Selsavage, CPA
Number Of Employees: 582
Enterprise Value: $111,850,565
PE Ratio: -0.07
Exchange/Ticker 1: NASDAQ:ME
Exchange/Ticker 2: N/A
Latest Market Cap: $31,387,500
BioCentury | Apr 4, 2025
Finance
1Q25 Wrap: Market backslide hits broad swath of companies
Winners, losers in biotech stock tiers in 1Q25
BioCentury | Nov 26, 2024
Deals
Kyowa Kirin brings global reach to Kura’s menin program via licensing deal
Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more
BioCentury | Sep 29, 2023
Management Tracks
Novartis veteran Fox to head Teva’s U.S. commercial business
Plus: Rich Scott succeeding Chris Wigley at Genomics England, and updates from Sonoma, PIC, Turbine and LCRF
BioCentury | Apr 19, 2023
Data Byte
ADCs overtake mAbs in AACR’s first-in-human abstracts
BioCentury’s analysis of 25 first-in-human studies presented at AACR 2023
BioCentury | Apr 18, 2023
Management Tracks
Kjems becomes CMO at Ocelot
Plus: New CFO at RS and updates from Tessera and ReCode
BioCentury | Sep 20, 2022
Management Tracks
Luo joins Everest as CEO
Plus Hitchcock named CSO at Takeda, and updates from Viracta, Agios, Aktis and more
BioCentury | Apr 26, 2022
Management Tracks
Stoffels becomes Galapagos board chairman
Plus Vedere Bio II and management moves at Jnana, Flare, DeepCure and more
BioCentury | Dec 17, 2021
Product Development
How digital is evolving at pharmas
The definition of digital is coming into focus at pharmas as data science becomes the central value driver
BioCentury | Dec 1, 2021
Management Tracks
Grauer becomes CMO at Federation Bio
Plus: LabGenius, 23andMe, Vifor, Immunovia, Forma and more
BioCentury | Nov 20, 2021
Politics, Policy & Law
LDT policy: back to murky
FDA’s LDT policy has gone full circle from murky to terrible and back; next year may be better
Items per page:
1 - 10 of 10